Industry reports
Editor highlights

Publication dates

Growth Hormone Research Reports, April 2014

You might be interested in: protein, drug delivery, human growth hormone, more »


 

1-10 of 35 reports for Growth Hormone
Prolor Biotech, Inc. (PBTH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Prolor Biotech, Inc. (PBTH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Industry report
  • February 2014
  • by Global Data

... Longer life spans. Prolor's product pipeline comprises human growth hormone (hgh), factor ix, anti-obesity peptide oxyntomodulin, factor viia, interferon and erythropoietin (epo) and atherosclerosis ...

Merger & Acquisition in Pharmaceuticals & Healthcare Industry: SciGen Limited (SIE)

Merger & Acquisition in Pharmaceuticals & Healthcare Industry: SciGen Limited (SIE)

  • $ 250
  • Industry report
  • February 2014
  • by Global Data

... And markets recombinant human health care biotechnology derived products. Its products include recombinant human growth hormone, second generation recombinant human insulin, and recombinant human granulocyte ...

Global Biosimilar Market Outlook 2018

Global Biosimilar Market Outlook 2018

  • $ 1 500
  • Industry report
  • February 2014
  • by RNCOS

... We have segmented the biosimilars market into various categories such as epo (erythropoietin), hgh (human growth hormone), ifn (interferon), mab (monoclonal antibody), insulin and g-csf (granulocyte ...

Versartis, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Versartis, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

... For the treatment of endocrine disorders. Its product under clinical development includes vrs-317 (hgh). Versartis's vrs-317 is a human growth hormone (hgh), which consists of recombinant human growth hormone (rh ...

Phage Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Phage Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

... On protein products division manufactures and sells recombinant protein pharmaceuticals. Its nasal delivery of protein products consist of nasal growth hormone, nasal beta interferon, nasal g-csf and nasal pth ...

Ambrx, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Ambrx, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

... S program arx-201 is a long-acting human growth hormone. The company's second advanced project is arx424 for the treatment of multiple sclerosis. Its recode technology confers unprecedented control over ...

Analysis of the Global Biosimilars Market

Analysis of the Global Biosimilars Market

  • $ 10 000
  • Industry report
  • January 2014
  • by Frost & Sullivan

... This time period. Regulatory guidelines have been drafted by the ema for erythropoietins (epo), granulocyte colony stimulating factors (g-csf), human growth hormone (hgh), and monoclonal antibodies (m ...

Biotech API Manufacturing Services: World Industry and Market 2014-2024

Biotech API Manufacturing Services: World Industry and Market 2014-2024

  • $ 2 776
  • Industry report
  • December 2013
  • by Visiongain

... Expected overall to 2024 for drug classes - see forecasts for monoclonal antibodies (mabs), insulins, growth hormones, interferons, and vaccines.And you also explore these aspects of the field ...

Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018

Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018

  • $ 4 650
  • Industry report
  • November 2013
  • by MarketsandMarkets

... Market is further segmented as insulin, granulocyte colony-stimulating factor (g-csf), interferons, and human growth hormone, whereas the recombinant glycosylated proteins market is further broken down ...

Commercialisation of Biosimilars: strategies for market penetration

Commercialisation of Biosimilars: strategies for market penetration

  • $ 495
  • Industry report
  • November 2013
  • by Firstword Pharma

... Relationships with payers 3.2.4.5.Countering defensive strategies 4.The us market 4.1.Overview 4.2.Experience to date 4.2.1.Human growth hormone (hgh) 4.2.2.M-enoxaparin 4.2.3.Tbo ...


ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.